Articles by tag: car-t-therapy

CAR-T therapy for lupus: 100% remission in a small cohort

German rheumatologists achieved 100% remission in lupus with CAR-T. Four-year data, immune reset mechanism, and forecasts. Read.

CAR-T therapy against aging: elimination of senescent cells

An international consortium has developed CAR-T for selective elimination of senescent cells. Learn how uPAR CAR-T technology fights age-related diseases and fibrosis.

CAR-T therapy for ovarian cancer: lira-cel and 28 months of life

Updated Phase I data: CAR-T lira-cel showed 28-month survival in ovarian cancer. Learn why this is a breakthrough in solid tumor treatment.

Lymphoma metabolism: new vulnerabilities for CAR-T therapy

Nature reveals metabolic subtypes of DLBCL. Learn how glycolysis and lipid inhibitors enhance CAR-T efficacy. Read market forecast until 2028.

Dual-action CAR-T: 100% remission in myeloma at ISCT 2026

ISCT 2026 data analysis: CAR-T therapy TPST-2003 showed complete response in all naive patients. Learn why this is a breakthrough, not an illusion, and what risks are hidden.